Researchers reported on the clinical response of a patient with psoriatic nail dystrophy and psoriatic arthritis who received treatment with tildrakizumab.
Researchers identified patients who were more likely to achieve the Clinical Disease Activity for Psoriatic Arthritis treatment targets of remission or low disease activity with apremilast, using a pooled analysis of the PALACE studies.
Researchers evaluated the risk for adverse events, including serious infections, among patients with self-reported psoriatic arthritis compared with those with psoriasis.
Researchers studied the effect of secukinumab on enthesitis resolution in patients with psoriatic arthritis, using pooled data from the FUTURE 2 and 3 trials.
Researchers evaluated the effect of clinical specialty setting and geographic region on the management of patients with psoriatic arthritis in the United States.
Investigators created checklists and templates based on the opinions of rheumatologists and radiologists in an effort to standardize MRI assessment of the spine and sacroiliac joints in patients with axial spondyloarthritis and/or inflammatory spinal pain.
Researchers evaluated the microbial characteristics driving ankylosing spondylitis pathogenesis, and they examined the effects of tumor necrosis factor inhibitor therapy on the microbiome.
IL-17 and IL-23 inhibitors appear to be well tolerated, with good safety profiles; recent findings outlined here may aid clinical decision making when choosing the most appropriate therapy for patients with moderate to severe psoriasis.
